Our approach

Harnessing the Therapeutic Potential of Keystone Bacteria to Develop Single-Strain LBPs

With our growing understanding of the microbiome, we are at the dawn of an era that will revolutionize the way we approach and develop new treatments for chronic disease.

The key to the gut microbiome is balance. The more rich and diversified your gut bacteria are, the lower your risk of developing an illness. Many scientific publications have highlighted the link between an imbalance of the microbiome – dysbiosis – and the onset of chronic disease. 

That’s how we first started using commensal bacteria to restore the balance of our gut microbiome, and how a new class of medication emerged: Live Biotherapeutic Products, or LBPs.

LNC Therapeutics has chosen to develop single-strain LBPs, which use a bacterial strain that has been specifically selected for each drug candidate.

more +

LBPs contain beneficial live bacteria, which are administered orally to treat diseases like obesity, type 2 diabetes and inflammatory, cardiovascular and neurodegenerative diseases. They are produced from isolated bacterial strains, taken mostly from the human gut, which are cultivated ex-vivo in compliance with pharmaceutical quality standards, and then reintroduced into the human body as capsules or pills to be taken orally. 

Single-Strains Bacteria are the Next Frontier in Microbiome Therapies

Of the billions of bacteria that make up our body, certain families are considered keystone taxa of the microbiome, playing a fundamental role in the host’s health.

At LNC, we are convinced that single bacterial strains will form the next generation of innovative gut microbiome-based medicine, as they address the fundamental causes of gut dysbiosis. Our added value consists in selecting from among these families of keystone bacteria those with strong therapeutic potential to restore missing functions, having already demonstrated proof of concept, to bring them into the clinical development phase.

A Small Shift can Provide Great Benefits

Keystone bacteria are the foundation of the whole ecosystem because they provide very specific metabolic functions that support other generalist micro-organisms. 

Our gut microbiome is made up of 3 categories of bacteria: dominant bacteria, subdominant bacteria and opportunistic pathogens.

Keystone bacteria act as immune primers as they send unique signals to immune cells, which in turn respond to tolerate the beneficial organisms to form the basis of a mutualistic relationship. 

Keystone bacteria produce basic metabolic compounds that serve as building blocks to feed other bacteria that subsequently produce beneficial molecules through a domino effect. 

Contrarily to dominant bacteria, keystones are often subdominant slow growers that set the scene for the fast growers. Together, they establish a balance that keeps pathogens at bay through control of nutrient sources and production of antimicrobials.

Microbiome & us
News
Feb 3, 2020
We are looking for Administrative and Finance Assistant | WHAT WE OFFER An exciting opportunity to dive in and begin...
> more
Jan 13, 2020
We are looking for Clinical Project Manager | WHAT WE OFFER An exciting opportunity to dive in and begin your career...
> more
Press / Media
Nov 12, 2019
Biotechs investments disrupt Big Pharma business model The pharmaceutical industry is in a state of flux, with...
> more
Sep 6, 2019
Chaque semaine, Maddyness dresse le bilan des levées de fonds de la semaine qui vient de s’écouler. Cette semaine,...
> more
Publications
Dec 6, 2019
The term “microbiome” refers to the collection of microorganisms (or microbiota) – including bacteria, viruses and...
> more
Oct 28, 2019
Jillian L. Waters, Ruth E. Ley The Christensenellaceae, a recently described family in the phylum Firmicutes, is emerging...
> more
now on twitter
LNC Therapeutics

In a large human study Dr Katerina Johnson found that both gut microbiome composition and diversity were related to… t.co/eufMEnGuo4

LNC Therapeutics © 2020 - all rights reserved terms and conditions